Wang Ying, Zeng Guilin, Jiang Yicheng
Department of Oncology, The Fifth People's Hospital of Chengdu, Chengdu, People's Republic of China.
Department of Oncology, The People's Hospital of Chongqing Hechuan, Chongqing, People's Republic of China.
Cancer Manag Res. 2020 Feb 12;12:1079-1088. doi: 10.2147/CMAR.S232388. eCollection 2020.
MicroRNAs (miRNAs) are endogenous, noncoding, single-stranded RNA molecules of 22 nucleotides in length. MiRNAs have both tumor-suppressive properties and oncogenic properties that can control critical processes in tumors. Mature miR-125b originates from miR-125b-1 and miR-125b-2 and leads to the degradation of target mRNAs or the inhibition of translation through binding to the 3' untranslated regions (3'-UTR) of target mRNAs. Importantly, miR-125b is involved in regulating NF-κB, p53, PI3K/Akt/mTOR, ErbB2, Wnt, and another signaling pathways, thereby controlling cell proliferation, differentiation, metabolism, apoptosis, drug resistance and tumor immunity. This review aims to summarize the recent literature on the role of miR-125b in the regulation of tumorigenesis and to explore its potential clinical application in the diagnosis, prognosis and clinical treatment of tumors.
微小RNA（miRNA）是长度为22个核苷酸的内源性非编码单链RNA分子。miRNA具有肿瘤抑制特性和致癌特性，可控制肿瘤中的关键过程。成熟的miR-125b起源于miR-125b-1和miR-125b-2，并通过与靶mRNA的3'非翻译区（3'-UTR）结合导致靶mRNA降解或抑制翻译。重要的是，miR-125b参与调节NF-κB、p53、PI3K/Akt/mTOR、ErbB2、Wnt及其他信号通路，从而控制细胞增殖、分化、代谢、凋亡、耐药性和肿瘤免疫。本综述旨在总结近期关于miR-125b在肿瘤发生调控中作用的文献，并探讨其在肿瘤诊断、预后和临床治疗中的潜在临床应用。
